propranolol has been researched along with Eye Abnormalities in 16 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Eye Abnormalities: Congenital absence of or defects in structures of the eye; may also be hereditary.
Excerpt | Relevance | Reference |
---|---|---|
"Oral propranolol is widely considered to be first-line therapy for complicated infantile hemangioma, but its use in patients with PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome has been debated owing to concerns that the cardiovascular effects of the drug may increase the risk for arterial ischemic stroke." | 3.96 | Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome. ( Adams, D; Baselga, E; Chamlin, S; Drolet, BA; Frieden, IJ; Frommelt, P; Garzon, MC; Gupta, D; Hansen, LM; Horii, K; Klajn, J; Lauren, C; Maheshwari, M; Mancini, AJ; Mathes, E; McCuaig, CC; Newell, B; Nguyen, HL; Nopper, A; Olsen, GM; Powell, J; Puttgen, KB; Siegel, DH; Stefanko, NS; Tollefson, MM, 2020) |
"Propranolol treatment was safe in our patients who did not show signs of perfusion changes." | 1.38 | Brain perfusion SPECT in patients with PHACES syndrome under propranolol treatment. ( Coya, J; Hernandez-Martin, S; Lopez-Fernandez, S; Lopez-Gutierrez, JC; Marin, D; Miguel, M; Ramírez, M; Tovar, JA, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (75.00) | 24.3611 |
2020's | 4 (25.00) | 2.80 |
Authors | Studies |
---|---|
Kleinman, EP | 1 |
Blei, F | 1 |
Adams, D | 2 |
Greenberger, S | 1 |
Lim, TH | 1 |
Yap, E | 1 |
Norhatizah, BS | 1 |
Olsen, GM | 1 |
Hansen, LM | 1 |
Stefanko, NS | 1 |
Mathes, E | 1 |
Puttgen, KB | 1 |
Tollefson, MM | 1 |
Lauren, C | 1 |
Mancini, AJ | 1 |
McCuaig, CC | 1 |
Frieden, IJ | 3 |
Baselga, E | 2 |
Chamlin, S | 1 |
Gupta, D | 1 |
Frommelt, P | 1 |
Garzon, MC | 1 |
Horii, K | 1 |
Klajn, J | 1 |
Maheshwari, M | 1 |
Newell, B | 1 |
Nguyen, HL | 1 |
Nopper, A | 1 |
Powell, J | 1 |
Siegel, DH | 1 |
Drolet, BA | 1 |
Sazali, HB | 1 |
Allen, NM | 1 |
Murphy, A | 1 |
Czechowicz, JA | 1 |
Benjamin, T | 1 |
Bly, RA | 1 |
Ganti, SN | 1 |
Balkin, DM | 1 |
Perkins, JA | 1 |
Rosbe, KW | 2 |
Goldberg, V | 1 |
Martinez, B | 1 |
Cnop, K | 1 |
Rohloff, P | 1 |
Disse, SC | 1 |
Zemlin, M | 1 |
Mueller, C | 1 |
Meyer, S | 1 |
Bangiyev, JN | 1 |
Gurgel, R | 1 |
Vanderhooft, SL | 1 |
Grimmer, JF | 1 |
Solman, L | 1 |
Glover, M | 1 |
Beattie, PE | 1 |
Buckley, H | 1 |
Clark, S | 1 |
Gach, JE | 1 |
Giardini, A | 1 |
Helbling, I | 1 |
Hewitt, RJ | 1 |
Laguda, B | 1 |
Langan, SM | 1 |
Martinez, AE | 1 |
Murphy, R | 1 |
Proudfoot, L | 1 |
Ravenscroft, J | 1 |
Shahidullah, H | 1 |
Shaw, L | 1 |
Syed, SB | 1 |
Wells, L | 1 |
Flohr, C | 1 |
Rotter, A | 1 |
Samorano, LP | 1 |
Rivitti-Machado, MC | 1 |
Oliveira, ZNP | 1 |
Gontijo, B | 1 |
Rokugo, Y | 1 |
Ota, C | 1 |
Kimura, M | 1 |
Sasahara, Y | 1 |
Bellaud, G | 1 |
Puzenat, E | 1 |
Billon-Grand, NC | 1 |
Humbert, P | 1 |
Aubin, F | 1 |
Hoeger, PH | 1 |
Harper, JI | 1 |
Bonnet, D | 1 |
Boon, LM | 1 |
Ciofi Degli Atti, M | 1 |
El Hachem, M | 1 |
Oranje, AP | 1 |
Rubin, AT | 1 |
Weibel, L | 1 |
Léauté-Labrèze, C | 1 |
El Rassi, E | 1 |
MacArthur, CJ | 1 |
Hernandez-Martin, S | 1 |
Lopez-Gutierrez, JC | 1 |
Lopez-Fernandez, S | 1 |
Ramírez, M | 1 |
Miguel, M | 1 |
Coya, J | 1 |
Marin, D | 1 |
Tovar, JA | 1 |
Durr, ML | 1 |
Meyer, AK | 1 |
Huoh, KC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas[NCT04651049] | 128 participants (Actual) | Observational | 2010-07-15 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for propranolol and Eye Abnormalities
Article | Year |
---|---|
Sirolimus for diffuse intestinal infantile hemangioma with PHACE features: systematic review.
Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Pr | 2023 |
PHACE syndrome: clinical manifestations, diagnostic criteria, and management.
Topics: Aortic Coarctation; Brain; Eye Abnormalities; Face; Facial Neoplasms; Hemangioma; Humans; Infant; Ma | 2018 |
Treatment of infantile haemangiomas: recommendations of a European expert group.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aortic Coarctation; Cryotherapy; Diagnosis, Di | 2015 |
13 other studies available for propranolol and Eye Abnormalities
Article | Year |
---|---|
Facial segmental haemangioma with PHACE Syndrome successfully treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Disease Progression; Eye Abno | 2019 |
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Cohort Studies; Eye Abnormali | 2020 |
PHACE syndrome: importance of distinguishing infantile haemangioma from capillary malformation.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Diagnosis, Differential; Eye Abnormalities; Female; | 2020 |
Airway Hemangiomas in PHACE Syndrome: A Multicenter Experience.
Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Ne | 2021 |
Use of propranolol in a remote region of rural Guatemala to treat a large facial infantile haemangioma.
Topics: Aortic Coarctation; Diagnosis, Differential; Eye Abnormalities; Face; Female; Guatemala; Hemangioma; | 2017 |
PHACE Syndrome-before and after Propranolol Therapy.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Eye Abnormalities; Female; Humans; Infant; Neurocut | 2018 |
Reversible profound sensorineural hearing loss due to propranolol sensitive hemangioma in an infant with PHACE syndrome.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Eye Abnormalities; Hearing Loss, Sensorineural; Hem | 2017 |
Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.
Topics: Administration, Oral; Aortic Coarctation; Clinical Decision-Making; Consensus; Delphi Technique; Der | 2018 |
Preoperative administration of propranolol reduced the surgical risks of PHACES syndrome in a 14-month-old girl.
Topics: Abnormalities, Multiple; Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Aort | 2019 |
PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
Topics: Aortic Coarctation; Child; Child, Preschool; Eye Abnormalities; Facial Neoplasms; Female; Hemangioma | 2015 |
Propranolol-responsive cranial nerve palsies in a patient with PHACES syndrome.
Topics: Aortic Coarctation; Bell Palsy; Eye Abnormalities; Hemangioma; Humans; Infant; Neurocutaneous Syndro | 2015 |
Brain perfusion SPECT in patients with PHACES syndrome under propranolol treatment.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Brain; Eye Abnormalities; Female; Humans; Infant; I | 2012 |
Airway hemangiomas in PHACE syndrome.
Topics: Aortic Coarctation; Bronchoscopy; Disease-Free Survival; Eye Abnormalities; Female; Follow-Up Studie | 2012 |